Sarepta may have seen off another rival in Wave

Wave Life Sciences has joined the biopharma sector's gold rush to treat DMD, a genetic disorder that causes progressive musculoskeletal disability in boys. So far,...

FTC demands could mean months-long delay for Roche-Spark deal

Roche's $4.8 billion takeout of gene therapy specialist Spark Therapeutics looked like a typical biopharma transaction — that is, until the Federal Trade Commission got...

AstraZeneca inks ambitious $6.9B deal for Daiichi cancer therapy

Long known for its prowess in cardiovascular and respiratory diseases, AstraZeneca has joined its pharmaceutical peers in making a bigger play in oncology. While the British...

Sangamo backs up early success for hemophilia gene therapy

In gene therapy, where dramatic results in deadly diseases can hasten clinical testing, studies tend to be smaller, with greater significance put on each...
Denali started 2018 with one research agreement with Takeda and is now ending the year with another big pharma collaboration. The Takeda deal, announced in...
Dive Insight: Anytime a PD-(L)1 inhibitor can beat Keytruda (pembrolizumab) to the market in a specific type of cancer, it should be celebrated as a...
The cancer field's largest conference has come and gone, and with it a window into the thousands of clinical trials being run in hopes...

Follow RXMonthly

News

Novo faces shareholder suit over insulin sales disclosures

Novo is best known for its insulin products like Levemir (insulin detemir) and Tresiba (insulin degludec), as well as other diabetes treatments...

FDA’s Woodcock defends accelerated approvals and talks of culture...

Over more than three decades at the Food and Drug Administration, Janet Woodcock has seen the biotech industry mature from the early days of...

Roche cancer drug the 3rd approved for pan-tumor use

Aimed at the molecular catalysts of tumor growth, targeted therapies are treatment mainstays across a wide range of cancer types. 

Safety setback for Pfizer, Lilly pain drug should have...

The U.S. opioid crisis breathed new life into clinical development of the nerve-growth factor (NGF) inhibitors tanezumab and fasinumab. The drug class had been...

Latest articles

CMS chief declines to provide details on Trump healthcare plan

The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation focused...

Roche cancer drug the 3rd approved for pan-tumor use

Aimed at the molecular catalysts of tumor growth, targeted therapies are treatment mainstays across a wide range of cancer types. 

Novo faces shareholder suit over insulin sales disclosures

Novo is best known for its insulin products like Levemir (insulin detemir) and Tresiba (insulin degludec), as well as other diabetes treatments like...

Celgene wins approval for drug key to Bristol buyout

Approval of Inrebic, which was previously known as fedratinib, is the first domino to fall in Bristol-Myers bet on Celgene's product pipeline. 

Subscribe to our newsletter